Health Care • Biotechnology: Pharmaceutical Preparations
$22.01 ▲ +0.40
(+1.85%)
MKT CAP: $1.36B • VOL: 460.3K
52W L $5 52W H $38
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
DMRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$210.9M | -$22.3M | -$39.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$209.8M | -$21.4M | -$38.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.7M | -$18.6M | -$36.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$6.7M | -$18.6M | -$36.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $257.6M | $14.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $240.4M | $15.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DMRA.